Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Yiqian Ni
Feasibility of Continuing Crizotinib Therapy After RECIST-PD in Advanced Non-Small Cell Lung Cancer Patients With ALK/ROS-1 Mutations
Journal of Cancer
Oncology
Related publications
Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer With ALK-rearrangement: A Brief Report
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients
PLoS ONE
Multidisciplinary
Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer
American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer Research
Oncology
P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China
PLoS ONE
Multidisciplinary
